Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $38.00. The company’s shares opened today at $15.36.
According to TipRanks, Belanger is a 4-star analyst with an average return of 6.5% and a 46.92% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Liquidia Technologies, and Cytokinetics.
KalVista Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $43.00.
See today’s best-performing stocks on TipRanks >>
Based on KalVista Pharmaceuticals’ latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $24.11 million. In comparison, last year the company had a GAAP net loss of $14.96 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
Read More on KALV:
- ShiftPixy (NASDAQ:PIXY) Soars on Spin-off Plans; Dual Listing
- Should Investors Buy LOW Stock at Current Levels?
- Got a Buy List Ready? Analysts Think These 2 ‘Strong Buy’ Stocks Should Be On It
- Apple (AAPL): New Buy Recommendation for This Technology Giant
- Cineworld files for Chapter 11 bankruptcy in the U.S.
